¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"group Ia inhibition"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • ABO blood group system
    ABOÇ÷¾×Çüü°è
  • amino group
    ¾Æ¹Ì³ë±â
  • basic food group
    ±âÃʽÄǰ±º
  • blood group
    Ç÷¾×Çü
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ
  • blood group system
    Ç÷¾×Çüü°è
  • coliform group
    ´ëÀå±Õ±º
  • complementation group
    »óº¸¼ºÁý´Ü
  • control group
    ´ëÁ¶±º
  • determinant group
    °áÁ¤±º
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • end group
    ¸»´Ü±â
  • enteric group
    âÀÚ±Õ±º, Àå±Õ±º
  • functional group
    ÀÛ¿ë±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • selective inhibition
    ¼±ÅþïÁ¦
  • migration inhibition test
    À̵¿¾ïÁ¦°Ë»ç, À̵¿ÀúÁö°Ë»ç
  • reciprocal inhibition psychotherapy
    »óÈ£¾ïÁ¦Á¤½Å¿ä¹ý
  • ABO blood group system
    ¿¡À̺ñ¿ÀÇ÷¾×Çü±º
  • amino group
    ¾Æ¹Ì³ë±â
  • atomic group
    ¿øÀÚ´Ü
  • group antigen
    ±ºÇ׿ø
  • group audiometry
    Áý´Üû·Â°Ë»ç
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • basic food group
    ±âÃʽÄǰ±º
  • blood group
    Ç÷¾×Çü
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ
  • blood group system
    Ç÷¾×Çü±º
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • borderline group
    °æ°è±º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inhibition test, migration
    À¯ÁÖ¾ïÁ¦½ÃÇè, À¯ÁÖÀúÁö½ÃÇè
  • inhibition zone
    ¾ïÁ¦´ë(åäð¤Óá).
  • inhibition(-tory) factor, macrophage migration
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
  • inhibition, allogeneic
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • inhibition, contact
    Á¢Ã˼º Áõ½Ä¾ïÁ¦
  • inhibition, fertility
    FÀÎÀÚ Àü´ÞÀúÁö, ¼öÅÂÀÎÀÚ Àü´ÞÀúÁö
  • postsynaptic inhibition
    ½Ã³³½ºÈľïÁ¦ (¡­ý­åäð¤).
  • postsynaptic inhibition
    ¿¬Á¢ÈľïÁ¦
  • presynaptic inhibition
    ½Ã³³½ºÀü¾ïÁ¦ (¡­åäð¤).
  • presynaptic inhibition
    ½Å°æÁ¢ÇÕÀü ¾ïÁ¦
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦(ßÓÚãåäð¤).
  • reciprocal inhibition
    »óÈ£¾ïÁ¦
  • reciprocal inhibition psychotherapy
    »óÈ£Á¦ÁöÁ¤½ÅÄ¡·á.
  • recurrent inhibition
    ¹Ý·ù(¼º) ¾ïÁ¦(Úãêüàõ åäð¤).
  • ABO blood group
    ABO Ç÷¾×Çü.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • indirect inhibition
    °£Á¢¾ïÁ¦.
  • inhibition
    ¾ïÁ¦,±ÝÁö
  • inhibition
    ¾ïÁ¦
  • inhibition
    ¾ïÁ¦.
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • inhibition
    ¾ïÁ¦
  • inhibition reaction
    ¾ïÁ¦(¹ÝÀÀ), ÀúÁö(¹ÝÀÀ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
  • multivalent allosteric inhibition
    ´Ù°¡(Òýʤ) ¾Ë·Î½ºÅ׸®ÀúÇØ(îÁúª)
  • multivalent feedback inhibition
    ´Ù°¡(Òýʤ) µÇ¸ÔÀÓÀúÇØ(îÁúª)
  • noncompetitive inhibition
    ºñ°áÇÕ ÀúÇØ(ު̿ùêîÁúª)
  • parabolic inhibition
    Æ÷¹°¼±Çü(øØÚªàÊû¡) ÀúÇØ(îÁúª)
  • partial inhibition
    ºÎºÐ ÀúÇØ(Ý»ÝÂîÁúª)
  • polyvalent allosteric inhibition
    ´Ù°¡(Òýʤ) ¾Ë·Î½ºÅ׸® ÀúÇØ(îÁúª)
  • product inhibition
    »ê¹°ÀúÇØ(ß§ÚªîÁúª)
  • pseudofeedback inhibition
    À§(êÊ)µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • sequence feedback inhibition
    ¼­¿­(ßíÖª) µÇ¸ÔÀÓÀúÇØ(îÁúª)
  • substrate inhibition
    ±âÁúÀúÇØ (ÐñòõîÁúª)
  • suicide inhibition
    ÀÚ¸ê ÀúÇØ(í»ØþîÁúª)
  • total inhibition
    ÀüÀúÇØ(îïîÁúª)
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • acetyl group
    ¾Æ¼¼Æ¿±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MIF   1) Mllerian Inhibiting Factor
  2) Migrating Inhibition Factor
TBII TSH Binding Inhibiting(= Inhibition) Immunoglobulin
AGPI agar gel precipitin inhibition
CFI chemotactic-factor inactivator; closed-clenched fist injury; color flow imaging; complement fixation...
CI cardiac index; cardiac insufficiency; cell immunity; cell inhibition; cephalic index; cerebral infar...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
group II group I
Group III group
ACEi Angiotensin I converting enzyme inhibition
BIS Behavioral Inhibition System
CEI Converting enzyme inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Coxsackie virus group A
    A±º ÄÛ»çŰ ¹ÙÀÌ·¯½º
  • E-blood group
    ÀÌ½Ä Ç÷¾×Çü
    »ç¶÷ÀÇ Ç÷¾×ÇüÀÇ Çϳª. OÇü ÀÌ¿ÜÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ Áß¿¡¼­ ¹ìÀå¾îÀÇ Ç÷û ¼Ó¿¡ Á¸ÀçÇÏ´Â ÀÀÁý¼Ò¿¡ °­ÇÏ°Ô ¹ÝÀÀÇÏ´Â °ÍÀ» EÇü, ¹ÝÀÀÀÌ ¾àÇÑ °ÍÀ» eÇüÀ¸·Î ÇÏ´Â Ç÷¾×ÇüÀ» ¸»ÇÑ´Ù. EÇüÀº ABO½ÄÀÇ BÇü¿¡ °¡Àå ¸¹°í, A, AB ¼øÀ¸·Î ºóµµ°¡ ³·´Ù. ¶ÇÇÑ À¯ÀüÀÚÇü°úµµ °ü°è°¡ ÀÖÀ¸¸ç II, II
  • herpes group of virus
    Æ÷Áø¼º ¹ÙÀÌ·¯½º
  • high risk group
    °íÀ§Çèµµ±º
  • Lutheran blood group
    ·çÅ×¶õ½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ ÀÏÁ¾. ¿ì¿­ÀÌ ¾ø´Â ÇÑ ½ÖÀÇ ´ë¸³ À¯ÀüÀÚ Lu, Lu¿¡ ÀÇÇØ¼­ Áö¹èµÇ°í, ÀÌ À¯ÀüÀÚÀÇ Á¶ÇÕ¿¡ µû¶ó¼­ »ç¶÷ÀÇ Ç÷±¸´Â Lu
  • methyl green-pyronin of nucleolus

    methyl group

    ¸ÞÄ¥±â
  • myelinated group
    À¯¼öÃʱº
  • open group
    °ø°³ Áý´Ü
  • posterior group nuclei
    ÈĺΠÇÙ
  • posterior nuclear group
    ÈÄÇÙ Áý´Ü
  • prosthetic group
    ¹èÇÕ±º
  • Q : Àü±â·®ÀÇ coulombÀÇ ±âÈ£.

    Q blood group system

    Å¥½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ Çϳª. µÅÁö Ç÷ûÀÇ ¾î¶² °Í¿¡ Á¸ÀçÇÏ´Â Ç× Q ÀÀÁý¼Ò¸¦ °¡ÇßÀ» ¶§ ÀÀÁýÇϴ°¡ ÇÏÁö ¾Ê´Â°¡¿¡ µû¶ó Ç÷¾×À» ºÐ·ùÇÏ´Â °ÍÀÌ´Ù. Ç× QÀÀÁý¼Ò´Â P½Ä Ç÷¾×ÇüÀÇ Ç× P ÀÀÁý¼Ò¿Í µ¿ÀÏÇÑ °ÍÀ̶ó´Â Çм³µµ ÀÖ´Ù.
  • Rh blood group
    Rh Ç÷¾×Çü, ¾Æ¸£ ¿¡ÀÌÄ¡½Ä Ç÷¾×Çü
    1940³â ¹Ì±¹ÀÇ K. ¶õÆ®½´Å¸ÀÌ³Ê µî¿¡ ÀÇÇÏ¿© ¹ß°ßµÈ ÀÓ»óÀûÀ¸·Î ¾ÆÁÖ Áß¿äÇÑ Ç÷¾×Çü. Rh¶ó´Â °ÍÀº, óÀ½¿¡ À̰ÍÀ» °ËÃâÇϴµ¥ ÇÊ¿äÇÑ Ç×Ç÷ûÀ» ¾ò±â À§ÇÏ¿© »ç¿ëÇÑ ¸é¿ª µ¿¹°ÀÎ ºÓÀºÅпø¼þÀÌ
  • S-blood group
    ¿¡½º½Ä Ç÷¾×Çü
    ABO½Ä Ç÷¾×Çü°ú °ü°è ÀÖ´Â Ç÷¾×Çü. Ç÷¾×ÀÇ ºÐºñÇü, ºñºÐºñÇüÀÇ ºÐ·ù¶ó°í Çϸç, 1932³â µ¶ÀÏÀÇ F. ½ÃÇÁ°¡ ¹ß°ßÇÏ¿´´Ù. ABO½Ä Ç÷¾×Çü¿¡ ¼ÓÇÏ´Â Ç׿ø ¹°Áú
  • zymophore group
    È¿¼ÒÀÛ¿ëÁ·
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
inhibition 1. Arrest or restraint of a process.
2. <psychology> The interference with or prevention of a behavioural or verbal response even though the stimulus for that response is present; in psychoanalysis the unconscious restraining of an instinctual process.
Origin: L. Inhibere = to restrain, habere = to hold
(04 Jul 1999)
inhibition factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
tissue thromboplastin inhibition time A test used to identify lupus anticoagulant; the thromboplastin source used in the prothrombin test is diluted to increase sensitivity to inhibitors.
(05 Mar 2000)
end product inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
enzyme inhibition theory of narcosis That narcotics inhibit respiratory enzymes by suppression of the formation of high energy phosphate bonds within the cell.
(05 Mar 2000)
uncompetitive inhibition An inhibitory effect on a metabolic function, such as an enzyme, not based on competition for the binding site of the naturally occurring substrate, but on a different effect on the molecule whose function is being inhibited.
(05 Mar 2000)
feedback inhibition <biochemistry, physiology> The process of the end product of a particular metabolic reaction inhibiting an allosteric enzyme involved in that reaction as the reaction starts again, thus breaking the reaction cycle.
(09 Oct 1997)
zone of inhibition <microbiology> The area of no bacterial browth around an antimicrobial agent in the disk-diffusion test.
(09 Oct 1997)
lateral inhibition A simple form of information processing. The classic example is found in the eye, whereby ganglion cells are stimulated if photoreceptors in a well defined field are illuminated, but their response is inhibited if neighbouring photoreceptors are excited (an on field/off surround cell) or vice versa an off field/on surround cell. The effect of lateral inhibition is to produce edge or boundary sensitive cells and to reduce the amount of information that is sent to higher centres, a form of peripheral processing.
(18 Nov 1997)
leukocyte adherence inhibition test Test for cell-mediated antitumour immunity and related serum blocking factors based on the finding that leukocytes from cancer patients, but not from controls, when mixed in vitro with antigenic extracts of tumours of the same histological type, undergo a diminution in their normal adherence to glass surfaces. Sera from tumour-bearing patients block the lai reaction of their own leukocytes or those of other patients with the same type of tumour.
(12 Dec 1998)
ABO blood group <haematology> The major human blood type system which describes the oligosaccharide glycoprotein antigens found on the surface of human blood cells.
According to the type of antigen present, a person may be assigned a blood type of A, B, AB or O. A second type of antigen, the Rh factor, renders a positive or negative blood type. The ABO blood group system is important because it determines who can donate blood to or accept blood from whom.
Type A or AB blood will cause an immune reaction in people with type B blood and type B and AB blood will cause a reaction in people with type A blood.
Conversely, type O blood has no A or B antigens, so people with type O blood are universal donors.
And since AB blood already produces both antigens, people who are type AB can accept any of the other blood types without suffering an immune reaction.
(04 Jul 1999)
actinobacteria group A group of gram-positive, heterogeneous bacteria. This group encompasses a range of morphologically, physiologically, and chemically different organisms and includes bacteria that form cocci, short rods, irregular rods, and mycelia that fragment.
(12 Dec 1998)
alkyl group <chemistry> A funtional group on an organic molecule which is derived from an alkane which has lost a hydrogen atom.
(13 Nov 1997)
aluminum group Aluminum, boron, gallium, indium, and thallium.
(05 Mar 2000)
amino group <biochemistry> An -NH2 group. Organic compounds which have this group are called amines.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • group therapy
    Áý´Ü ¿ä¹ý
  • group velocity
    (ÆÄµ¿ÀÇ)±º¼Óµµ
  • group work
    Áý´Ü(»çȸ)»ç¾÷
  • habitat group
    »ýÅ·ù(¼­½Ä ȯ°æÀ» °°ÀÌ ÇÏ´Â µ¿½Ä¹°);(¹Ú¹°°ü¿¡ Àü½ÃµÈ)»ý¹° ȯ°æ ¸ðÇü
  • income group
    »çȸ ¼ÒµæÃþ(µ¿ÀÏ ¼Òµæ¼¼¾×Áý´Ü)
  • informal group
    (»çȸ)ºñ°ø½ÄÀû Áý´Ü(°üû°øÀåµî¿¡¼­ÀÇ)
  • interested group
    (»çȸ)ÀÌÀͰøµ¿Ã¼;°øÅëÀÌÇØ´Üü(±¹°¡ Á¤´çŬ·´µî)
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
  • rape group
    ÅäÀÇ(Åä·Ð)±×·ì
  • reference group
    ÁذŠÁý´Ü(°³ÀÎÀÌ ÀÚ±â ŵµ.ÆÇ´ÜÀÇ ±âÁØÀ¸·Î ¿©±â´Â ƯÁ¤ Áý´Ü)
  • splinter group
    ºÐÆÄ;¼Ò¼öÆÄ
  • tail group
    TAIL UNIT
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á